These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase-2 and -9 activity and myocardial apoptosis in rats with congestive heart failure. Song YH; Li BS; Chen XM; Cai H Int J Mol Med; 2008 Jan; 21(1):117-24. PubMed ID: 18097624 [TBL] [Abstract][Full Text] [Related]
4. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure]. Yang YJ; Zhang X; Zhu WL; Huang Y Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324 [TBL] [Abstract][Full Text] [Related]
5. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Cox MJ; Hawkins UA; Hoit BD; Tyagi SC Circulation; 2004 May; 109(17):2123-8. PubMed ID: 15117845 [TBL] [Abstract][Full Text] [Related]
6. [Tumor necrosis factor alpha and myocardial matrix metalloproteinases in left ventricular remodeling]. Wang XM; Yang LX; Zhu SJ; Yang YJ; Guo CM; Qi F; Wei L; Shi YK; Wang Y; Ren L Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):828-31. PubMed ID: 15634542 [TBL] [Abstract][Full Text] [Related]
7. Role of nitric oxide in matrix remodeling in diabetes and heart failure. Tyagi SC; Hayden MR Heart Fail Rev; 2003 Jan; 8(1):23-8. PubMed ID: 12652156 [TBL] [Abstract][Full Text] [Related]
8. MMP induction and inhibition in myocardial infarction. Lindsey ML Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764 [TBL] [Abstract][Full Text] [Related]
9. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284 [TBL] [Abstract][Full Text] [Related]
10. Matrix metallopropteinases in heart failure. Tousoulis D; Kampoli AM; Papageorgiou N; Antoniades C; Siasos G; Latsios G; Tsiamis E; Stefanadis C Curr Top Med Chem; 2012; 12(10):1181-91. PubMed ID: 22519448 [TBL] [Abstract][Full Text] [Related]
17. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051 [TBL] [Abstract][Full Text] [Related]
18. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Nishikawa N; Yamamoto K; Sakata Y; Mano T; Yoshida J; Miwa T; Takeda H; Hori M; Masuyama T Cardiovasc Res; 2003 Mar; 57(3):766-74. PubMed ID: 12618238 [TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. Yarbrough WM; Mukherjee R; Brinsa TA; Dowdy KB; Scott AA; Escobar GP; Joffs C; Lucas DG; Crawford FA; Spinale FG J Thorac Cardiovasc Surg; 2003 Mar; 125(3):602-10. PubMed ID: 12658202 [TBL] [Abstract][Full Text] [Related]